WO2021185051A1 - 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 - Google Patents
一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 Download PDFInfo
- Publication number
- WO2021185051A1 WO2021185051A1 PCT/CN2021/078081 CN2021078081W WO2021185051A1 WO 2021185051 A1 WO2021185051 A1 WO 2021185051A1 CN 2021078081 W CN2021078081 W CN 2021078081W WO 2021185051 A1 WO2021185051 A1 WO 2021185051A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fragment
- fusion protein
- seq
- sequence
- amino acid
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 127
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 127
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 23
- 201000010099 disease Diseases 0.000 title claims description 22
- 230000033115 angiogenesis Effects 0.000 title claims description 19
- 238000011282 treatment Methods 0.000 title description 11
- 230000002035 prolonged effect Effects 0.000 title description 3
- 239000012634 fragment Substances 0.000 claims abstract description 157
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 52
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 41
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 41
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims abstract description 29
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 72
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 72
- 229920001184 polypeptide Polymers 0.000 claims description 71
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- 108010075254 C-Peptide Proteins 0.000 claims description 13
- 102000007079 Peptide Fragments Human genes 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 230000003252 repetitive effect Effects 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 230000008685 targeting Effects 0.000 abstract description 4
- 150000001413 amino acids Chemical group 0.000 description 67
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 239000007924 injection Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 14
- 230000006872 improvement Effects 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 108010081667 aflibercept Proteins 0.000 description 9
- 229960002833 aflibercept Drugs 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 7
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000011587 new zealand white rabbit Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 4
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000003527 anti-angiogenesis Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108020001580 protein domains Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229960003876 ranibizumab Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000004127 vitreous body Anatomy 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- 108700036276 KH902 fusion Proteins 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229950000025 brolucizumab Drugs 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229950005748 conbercept Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102000009075 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065630 Iris neovascularisation Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710118186 Neomycin resistance protein Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000010147 shenghe Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to the field of biotechnology, in particular to a fusion protein and a preparation method and application thereof.
- the fusion protein can be used to treat ocular angiogenesis diseases and has a significantly prolonged half-life.
- Angiogenesis a physiological process of forming new vascular tissue from the original vascular tissue, plays an important role in the process of development and disease.
- Some serious eye diseases such as wet age-related macular degeneration, retinal vein occlusion, and macular edema caused by proliferative diabetes, their mechanism is closely related to angiogenesis.
- AMD eye disease
- the choroid's ability to clear senescent and dead cells weakens, and the remaining cell debris collects between the retina and choroid near the macula, forming glass Warts affect the blood supply to the eye, and cause irritation to produce inflammation and angiogenesis.
- hypoxic pressure Due to the influence of hypoxic pressure, the new blood vessel walls produced by this abnormal angiogenesis are very fragile and easily permeable, which can cause fluid loss and bleeding of the eyeball.
- wet AMD With the aging of the population, there is an urgent need for ocular anti-angiogenesis treatment, but there are few effective treatments. Still taking wet AMD as an example, if it cannot be treated in time within 3 years, the blindness rate will rise from nearly 20% to 75%. At present, there are nearly 500,000 wet AMD patients in my country, and about 40,000 new patients are added every year. At present, treatment of wet AMD mainly includes laser coagulation, photodynamic therapy, vitrectomy, injection of anti-angiogenesis drugs, injection of anti-angiogenesis peptides or proteins, and injection of stem cells/RNA interference.
- Neovascularization inhibitors especially multi-target combined inhibitors, are currently a hot spot in clinical ophthalmology at home and abroad.
- VEGF vascular endothelial growth factor
- FLT1 VEGFR1
- KDR VEGFR2
- FLT4 VEGFR3
- VEGF-A is the main target of monoclonal antibodies and is specifically expressed in vascular endothelial cells and peripheral blood mononuclear cells.
- VEGF-A 121 can be secreted freely; VEGF-A 165 can bind to heparin, a considerable part of it can bind to cells, but most can be freely secreted; VEGF-A 189 can bind to cells after secretion, and heparin It has a strong binding force to the extracellular matrix, and it can also be released in a soluble form through heparin, heparinase, and plasmin.
- VEGF-A 206 and VEGF-A 145 which are less expressed.
- the currently marketed recombinant fusion protein or antibody drugs (Bevacizumab, Ranibizumab, Aflibercept, Conbercept (listed only in China) and Brolucizumab) for the treatment of the above-mentioned fundus diseases are all anti-VEGF drugs, which need to be administered through direct vitreous injection.
- the administration period is 1-3 months.
- Vitreous puncture injection is not only complicated to operate, but also breaks the original completely enclosed structure of the eyeball.
- Each injection has a certain risk of infection. Therefore, this method of administration poses a lot of challenges for patients and physicians. With the same curative effect, how to achieve fewer injections and better patient compliance is the key to current research and development. For example, if the dosing cycle is extended to 4-6 months or even longer, the situation will be significantly improved. .
- the purpose of the present invention is to provide a fusion protein for the treatment of ocular angiogenesis diseases with a significantly prolonged half-life, as well as a preparation method and use thereof, to solve the problems in the prior art.
- one aspect of the present invention provides a fusion protein, which includes a hydrophilic repeat sequence fragment, an antagonistic VEGF fragment, and an immunoglobulin Fc fragment.
- the hydrophilic repeat sequence fragment is selected from a gelatin-like protein fragment or a polypeptide complex unit fragment.
- the hydrophilic repeat sequence fragment includes:
- polypeptide fragment whose amino acid sequence has more than 90% sequence identity with one of SEQ ID Nos. 28-29 and has the function of a) polypeptide fragment defined in a); or,
- the antagonistic VEGF fragment includes:
- the immunoglobulin Fc fragment includes:
- the immunoglobulin Fc fragment is of human origin.
- the fusion protein further includes a connecting peptide fragment.
- the connecting peptide fragment is rich in G, S and/or A.
- the connecting peptide fragment includes a polypeptide fragment having an amino acid sequence as shown in one of SEQ ID NOs. 42-43.
- the fusion protein further includes an Ang antagonistic fragment, and the Ang antagonistic fragment is selected from an Ang-1 antagonist fragment or an Ang-2 antagonistic fragment.
- the hydrophilic repeat sequence fragment is located at the N-terminus and/or C-terminus of the fusion protein, and the antagonistic VEGF fragment is located at the N-terminus or C-terminus of the immunoglobulin Fc fragment;
- the antagonistic VEGF fragment or the antagonistic Ang fragment is independently located at the N-terminus or the C-terminus of the immunoglobulin Fc fragment. End and C end.
- the amino acid sequence of the fusion protein includes the sequence shown in one of SEQ ID NO. 11-12, SEQ ID NO. 15-16, and SEQ ID NO. 18-19;
- the amino acid sequence of the fusion protein includes the sequence shown in SEQ ID NO. 20 and SEQ ID NO. 21, the sequence shown in SEQ ID NO. 22 and SEQ ID NO. 24, and the sequence shown in SEQ ID NO. 23 and SEQ ID.
- Another aspect of the present invention provides an isolated polynucleotide encoding the fusion protein.
- Another aspect of the present invention provides a construct containing the isolated polynucleotide.
- Another aspect of the present invention provides an expression system that contains the construct or the exogenous polynucleotide integrated into the genome.
- Another aspect of the present invention provides a method for preparing the fusion protein, including: culturing the expression system under suitable conditions to express the fusion protein, and isolating and purifying to provide the fusion protein.
- Another aspect of the present invention provides a pharmaceutical composition comprising the fusion protein or the culture of the expression system.
- Another aspect of the present invention provides the use of the fusion protein and the pharmaceutical composition in the preparation of medicines.
- the drug is selected from drugs used for diseases related to ocular angiogenesis.
- Figure 1A shows a schematic diagram of the pharmacokinetic results of group 1 of Example 6 of the present invention in the vitreous of New Zealand white rabbits.
- Figure 1B is a schematic diagram showing the pharmacokinetic results of group 2 of Example 6 of the present invention in the vitreous of New Zealand white rabbits.
- Figure 1C is a schematic diagram showing the pharmacokinetic results of group 3 of Example 6 of the present invention in the vitreous of New Zealand white rabbits.
- Figure 1D is a schematic diagram showing the pharmacokinetic results of group 4 of Example 6 of the present invention in the vitreous of New Zealand white rabbits.
- Fig. 2 is a schematic diagram showing the improvement rate of the average leakage area of the four-level spot of each group in Example 7 of the present invention.
- Fig. 3 is a schematic diagram showing the improvement rate of the average thickness of the subretinal hyperreflective signal material (SHRM) in each group in Example 7 of the present invention.
- SHRM subretinal hyperreflective signal material
- Fig. 4 is a schematic diagram showing the improvement of the spot rate and the leakage area of DR301AbB4 in Example 7 of the present invention.
- the inventor of the present invention unexpectedly discovered that the fusion protein composed of hydrophilic repeat sequence fragments, antagonistic VEGF fragments, and immunoglobulin Fc fragments, administered by intravitreal injection, has a shorter half-life in the serum, while The vitreous body shows a good half-life, so that the fusion protein has better targeting and has a good industrialization prospect. On this basis, the present invention has been completed.
- the first aspect of the present invention provides a fusion protein, which includes a hydrophilic repeat sequence fragment, an antagonistic VEGF fragment, and an immunoglobulin Fc fragment.
- the fusion protein provided by the present invention generally refers to the expression product of multiple genes obtained by DNA recombination technology.
- the fusion protein may be linear, and the antagonistic VEGF fragment contained therein may be a linear domain; the fusion protein may also have a structure similar to that of a monoclonal antibody, and the antagonistic VEGF fragment contained therein may also be derived from a single The Fab region of the cloned antibody (composed of light chain and Fd chain).
- the fusion protein when the antagonistic VEGF fragment is a linear domain, is also linear, which can include multiple domain fragments, and can form dimers through immunoglobulin Fc fragments, and can be
- the N or C-terminus of the dimer includes hydrophilic repeating sequence fragments to form a fusion protein including hydrophilic repeating sequence fragments, antagonistic VEGF fragments, and immunoglobulin Fc fragments.
- the antagonistic VEGF fragment is derived from the Fab region of a monoclonal antibody, that is, when the fusion protein has a structure similar to that of a monoclonal antibody
- the Fd chain can be fused with the immunoglobulin Fc fragment to form a dimer, that is, the fusion
- the protein has a structure similar to that of a monoclonal antibody, and can be further fused with hydrophilic repeating sequence fragments on the basis of this structure, for example, fused to the light chain or heavy chain ends (N or C terminal) of the monoclonal antibody similar structure to A fusion protein including hydrophilic repeat sequence fragments, antagonistic VEGF fragments, and immunoglobulin Fc fragments is formed.
- the fusion protein provided by the present invention may include hydrophilic repetitive sequence fragments, which usually do not contain serine (S) and threonine (T), and are prepared in prokaryotic or eukaryotic expression systems. During the process, there will be no problems with glycosylation. In addition, the unevenness of Asn(N) and Gln(Q) caused by the deamidation of Asn(N) and Gln(Q) and the unevenness of products caused by the increase of potential protease sites due to a large variety of amino acids, etc. None of the water-based repetitive sequence fragments will appear.
- the hydrophilic repeat sequence may be a gelatin-like protein fragment.
- the gelatin-like protein fragment is usually mainly composed of glycine (G), proline (P), alanine (A) and glutamic acid (E), and has the characteristic GXY ternary monomer (Triplet) of gelatin.
- G represents glycine (G)
- X and Y are independently selected from proline (P), alanine (A) or glutamic acid (E).
- the molecular weight of the gelatin-like protein fragment is too large, it is difficult to prepare recombinant expression. On the contrary, the molecular weight is too small to significantly extend the half-life.
- the amino acid length of the gelatin-like protein fragment may be 100-500; more preferably, the amino acid length of the gelatin-like protein fragment may be 150-500; further preferably, the amino acid length of the gelatin-like protein fragment Can be 200-400.
- the hydrophilic repeat sequence fragment includes:
- polypeptide fragment whose amino acid sequence has more than 90% sequence identity with one of SEQ ID Nos. 28 to 29 and has the function of the polypeptide fragment defined in a).
- amino acid sequence in b) specifically refers to: the amino acid sequence shown in one of SEQ ID Nos.
- 28 to 29 has been substituted, deleted, or added one or more (specifically, 1-50, 1- 30, 1-20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids, or added at the N-terminus and/or C-terminus
- the hydrophilic repeat sequence usually has a relatively high hydrophilicity and can be significantly increased. Large protein hydration radius and apparent molecular weight, after vitreous administration, larger apparent molecular weight can support a longer intraocular half-life and reduce the number of administrations.
- the amino acid sequence in b) may have a sequence identity of 90%, 93%, 95%, 97%, or 99% or more with one of SEQ ID Nos. 28-29.
- sequence identity refers to the percentage of identical residues in the sequences involved in the comparison.
- Calculation software known in the art can be used to calculate the sequence identity of the sequence of two or more entries, and these software can be obtained from, for example, NCBI.
- the hydrophilic repeat sequence may be a fragment of a polypeptide complex unit.
- the polypeptide composite unit fragment is usually a type of flexible polypeptide or protein composed of three amino acids: proline (P), alanine (A) and glutamic acid (E).
- P proline
- A alanine
- E glutamic acid
- the amino acid sequence is a polypeptide fragment of the polypeptide unit shown in SEQ ID No. 31 or SEQ ID No. 32.
- the polypeptide composite unit fragments need to have a suitable molecular weight. If the molecular weight is too large, it is difficult to prepare for recombinant expression. On the contrary, the molecular weight is too small to significantly increase the apparent molecular weight and prolong the half-life.
- the amino acid length of the polypeptide composite unit fragment may be 100-500; more preferably, the amino acid length of the polypeptide composite unit fragment may be 150-500; further preferably, the amino acid length of the polypeptide composite unit fragment Can be 200-400.
- the polypeptide composite unit fragment includes:
- amino acid sequence in d) A polypeptide fragment whose amino acid sequence has more than 90% sequence identity with SEQ ID No. 30 and has the function of the polypeptide fragment defined in c).
- the amino acid sequence in d) specifically refers to: the amino acid sequence shown in SEQ ID No. 30 has been substituted, deleted, or added one or more (specifically, 1-50, 1-30, 1- 20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids, or add one or more ( Specifically, it can be obtained from 1-50, 1-30, 1-20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids, and has A functional polypeptide fragment whose amino acid is the polypeptide fragment shown in SEQ ID No. 30, for example, can increase the hydration radius of the protein.
- the amino acid sequence in d) may have 90%, 93%, 95%, 97%, or 99% or more sequence identity with SEQ ID No. 30.
- the fusion protein provided by the present invention may include an antagonistic VEGF fragment.
- the antagonistic VEGF fragment may generally be a polypeptide or protein fragment capable of antagonizing VEGF.
- the antagonizing VEGF fragment may be the extracellular region of VEGFR (for example, Aflibercept and Conbercept); domain proteins with the function of antagonizing VEGF, including but Not limited to: DARPin, Anticalin, scFv (for example, Brolucizumab, etc.), Fab (for example, Ranibizumab, etc.), single domain antibodies, and the like.
- the antagonistic VEGF fragment may include:
- polypeptide fragment whose amino acid sequence has more than 90% sequence identity with one of SEQ ID Nos. 1 to 7 and has the function of the polypeptide fragment defined in e).
- amino acid sequence in f) specifically refers to: the amino acid sequence shown in one of SEQ ID Nos. 1 to 7 has been substituted, deleted, or added one or more (specifically, 1-50, 1- 30, 1-20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids, or added at the N-terminus and/or C-terminus One or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids and The obtained polypeptide fragment having the function of the polypeptide fragment shown in one of SEQ ID Nos.
- the amino acid sequence in f) may have a sequence identity of 90%, 93%, 95%, 97%, or 99% or more with one of SEQ ID Nos. 1-7.
- the antagonistic VEGF fragment is usually of human origin.
- the fusion protein provided by the present invention may include an immunoglobulin Fc fragment.
- the immunoglobulin Fc fragment is usually the heavy chain constant region or part of the immunoglobulin, has no antigen binding activity, and is the site where the antibody molecule interacts with effector molecules and cells.
- the immunoglobulin Fc fragment may include a CH2 domain, a CH3 domain and an immunoglobulin hinge region of IgG1, and the starting amino acid position of the hinge region can be adjusted by those skilled in the art.
- the immunoglobulin Fc fragment may include:
- h) A polypeptide fragment whose amino acid sequence has more than 90% sequence identity with one of SEQ ID Nos. 33 to 41 and has the function of a polypeptide fragment defined by g). Specifically, the amino acid sequence in h) specifically refers to: the amino acid sequence shown in one of SEQ ID Nos.
- the obtained polypeptide fragment with the function of the polypeptide fragment shown in one of SEQ ID Nos. 33 to 41 can make the antibody naturally form a dimer, which can form a divalent to improve protein activity, And the half-life of the antibody can be effectively increased through the mechanism of FC and FcRn binding.
- the amino acid sequence in h) may have 90%, 93%, 95%, 97%, or 99% or more identity (Sequence identity) with one of SEQ ID Nos. 33 to 41.
- the immunoglobulin Fc fragment is usually of human origin.
- the fusion protein provided by the present invention may also include connecting peptide fragments.
- the fusion protein may usually include a plurality of connecting peptide fragments. For example, at least part of the domains or each of the domains may be provided with a connecting peptide fragment.
- the connecting peptide fragment can usually be a flexible polypeptide composed of glycine (G), serine (S) and/or alanine (A) with a suitable length, so that adjacent protein domains can move freely relative to each other.
- the amino acid sequence of the connecting peptide fragment may include sequences such as (GS)n, (GGS)n, (GGSG)n, (GGGS)nA, (GGGGS)nA, (GGGGA)nA, (GGGGG)nA, etc. , Where n is selected from an integer between 1-10.
- the length of the amino acid sequence of the connecting peptide fragment may be 5-26.
- the connecting peptide fragment may include a polypeptide fragment having an amino acid sequence as shown in one of SEQ ID NOs. 42-43.
- the hydrophilic repetitive sequence fragments can be located at the N-terminus and/or C-terminus of the fusion protein independently or at the same time, and the antagonistic VEGF fragments can be located in the immune system.
- the hydrophilic repeat sequence fragment can be fused to a suitable position of the antibody, for example, can be independent Or at the same time at the N-terminus and/or C-terminus of the light chain in the Fab region, at the N-terminus of the Fd chain in the Fab region, or at the C-terminus of the immunoglobulin Fc fragment.
- the amino acid sequence of the fusion protein may include the sequence shown in one of SEQ ID NO. 11-12, SEQ ID NO. 15-16, and SEQ ID NO.
- the amino acid sequence of the fusion protein may include the sequence shown in SEQ ID NO. 20 and SEQ ID NO. 21, the sequence shown in SEQ ID NO. 22 and SEQ ID NO. 24, and the sequence shown in SEQ ID NO. 23 and SEQ ID.
- the apparent molecular weight of the fusion protein provided by the present invention is significantly larger than that of a protein without a hydrophilic repeat sequence, especially when the hydrophilic repeat sequence is fused with a bivalent VEGF-antagonizing polypeptide or protein domain.
- the apparent molecular weight of the formed complex is extremely large.
- the apparent molecular weight of the fusion protein including the hydrophilic repeat sequence fragment is significantly larger than that of the fusion protein not fused with the hydrophilic repeat sequence. Theoretically, the half-life of a fusion protein including a fragment of a hydrophilic repeat sequence in serum should have a additive effect.
- Fc can bind to FcRn on the surface of peripheral monocytes or endothelial cells.
- hydrophilic repeats will cause an increase in the radius of hydration (reducing glomerular filtration), and a complex with a serum half-life much longer than that of Aflibercept should be obtained.
- SEQ ID No. 1 SEQ ID No. 1
- the hydrophilic repeat sequence is fused to the N-terminus and C-terminus of the light chain, respectively, and the half-life of the resulting fusion protein in serum is Not only did it not extend further, it was significantly shortened, but the half-life in the vitreous body was greatly extended.
- the fusion protein provided by the present invention may also include an antagonistic Angiopoietin (Ang) fragment, and the antagonistic Ang fragment can form a bispecific fusion protein targeting VEGF/Ang-1/2 with the antagonistic VEGF fragment.
- the Ang-antagonizing fragment may be a fragment that antagonizes Ang-1 (Angiopoietin 1) or a fragment that antagonizes Ang-2 (Angiopoietin 2).
- the Ang-1 antagonistic fragment may be a polypeptide or protein domain capable of antagonizing Ang-1
- the Ang-2 antagonizing fragment may be a polypeptide or protein domain capable of antagonizing Ang-2.
- Ang-2 can play a regulatory role in angiogenesis and the survival, proliferation, migration, adhesion, and skeletal remodeling of endothelial cells, while maintaining vascular stability.
- Ang-2 binds to the receptor TEK/TIE2 and activates tyrosine kinase activity by inducing homodimerization.
- Ang-1 is necessary for angiogenesis and heart development during embryonic development. Under different conditions, it activates or inhibits angiogenesis, regulates the maturity and stability of blood vessels, as well as the interaction between endothelial cells, matrix and interstitium.
- Ang-2 and Ang-1 can competitively bind TEK/TIE2 to regulate the signal pathway of Ang-1.
- Ang-1/2 can act synergistically with VEGF to promote the migration and proliferation of endothelial cells, so it is also an angiogenesis signal.
- the Ang antagonistic fragment may include:
- polypeptide fragment whose amino acid sequence has more than 90% sequence identity with one of SEQ ID Nos. 8-9 and has the function of a polypeptide fragment defined by g).
- the amino acid sequence in j) specifically refers to: the amino acid sequence shown in one of SEQ ID No. 8-9 has been substituted, deleted, or added one or more (specifically, 1-50, 1- 30, 1-20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids, or added at the N-terminus and/or C-terminus One or more (specifically 1-50, 1-30, 1-20, 1-10, 1-5, 1-3, 1, 2, or 3) amino acids and
- the obtained polypeptide fragment having the function of the polypeptide fragment shown in one of SEQ ID Nos. 8-9 for example, can antagonize Ang-1 and/or Ang-2.
- the amino acid sequence in j) may be 90%, 93%, 95%, 97%, or 99% identical with one of SEQ ID Nos. 8-9.
- the antagonistic VEGF fragment and the antagonistic Ang fragment can be independently located at the N-terminus or C-terminus of the immunoglobulin Fc fragment.
- the antagonistic VEGF fragment and the antagonistic Ang fragment can be located at the N-terminus and C-terminus of the immunoglobulin Fc fragment, respectively.
- the hydrophilic repeat sequence fragments can be located at the N-terminus and/or C-terminus of the fusion protein independently or at the same time.
- the antagonistic VEGF fragment is derived from the Fab region of a monoclonal antibody, that is, the fusion protein has a structure similar to that of a monoclonal antibody
- the antagonistic Ang fragment may be located at the C-terminus of the immunoglobulin Fc fragment
- the hydrophilic repeat sequence fragment may be Independently or simultaneously located at appropriate positions of the fusion protein, for example, it may be located at the N-terminus and/or C-terminus of the light chain in the Fab region, the N-terminus of the Fd chain in the Fab region, or the C-terminus of the immunoglobulin Fc fragment.
- the amino acid sequence of the fusion protein may include the sequence shown in one of SEQ ID NO. 15, SEQ ID NO. 18, and SEQ ID NO. 19; or, the sequence of the fusion protein
- the amino acid sequence may include the sequence shown in SEQ ID NO. 22 and SEQ ID NO. 24, the sequence shown in SEQ ID NO. 23 and SEQ ID NO. 24, or the sequence shown in SEQ ID NO. 26 and SEQ ID NO. 27 the sequence of.
- the fusion protein (bispecific fusion protein) provided by the present invention includes hydrophilic repeating sequence fragments.
- the half-life of the formed fusion protein in the serum is not further extended, but is significantly shortened, while the half-life in the vitreous body is greatly reduced. Extended.
- the fusion protein in order to obtain a recombinant protein that is automatically secreted out of the host cell, or to facilitate the purification of the recombinant protein, some amino acids (for example, including but not limited to, suitable linker peptides, signal peptides, leader Peptides, end extensions, etc.) are added to the N-terminus, C-terminus and/or other suitable regions of the recombinant protein.
- the N-terminal and/or C-terminal of the fusion protein may also include one or more polypeptide fragments, and these polypeptide fragments may be protein tags and the like. Specifically, it can be, for example, FLAG, HA, Poly-His, GST, MBP, c-Myc, etc. These tags can be used to purify or detect proteins.
- the second aspect of the present invention provides an isolated polynucleotide encoding the fusion protein provided by the first aspect of the present invention.
- the third aspect of the present invention provides a construct containing the isolated polynucleotide provided in the second aspect of the present invention.
- the construct can usually be constructed by inserting the isolated polynucleotide into a suitable vector, and those skilled in the art can select a suitable expression vector.
- the type of the vector may include, but is not limited to, plasmids, phagemids, phage derivatives, animal viruses, cosmids, and the like.
- the vector may be an expression vector or a cloning vector.
- a suitable vector contains an origin of replication that functions in at least one organism, a promoter sequence, convenient restriction enzyme sites, and one or more selectable markers.
- promoters are: Escherichia coli lac or trp promoter; lambda phage PL promoter; eukaryotic promoters include CMV immediate early promoter, HSV thymidine kinase promoter, early and late SV40 promoter, Bi Red yeast methanol oxidase promoter and other known promoters that can control gene expression in prokaryotic or eukaryotic cells or their viruses.
- Marker genes can be used to provide phenotypic traits for selection of transformed host cells, including but not limited to dihydrofolate reductase, neomycin resistance, and green fluorescent protein (GFP) for eukaryotic cell culture, or for large intestine Bacillus resistance to tetracycline or ampicillin.
- GFP green fluorescent protein
- the fourth aspect of the present invention provides an expression system containing the construct provided by the third aspect of the present invention or the polynucleotide provided by the second aspect of the present invention integrated with an exogenous genome in the genome, so that the expression system can express all The fusion protein.
- the expression system may be a host cell, the host cell may be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; a filamentous fungal cell, or a higher eukaryotic cell, such as a mammalian cell .
- Escherichia coli, Streptomyces bacterial cells of Salmonella typhimurium
- fungal cells such as yeast, filamentous fungi, plant cells
- insect cells of Drosophila S2 or Sf9 CHO, COS, 293 cells, or Bowes black Tumor cells, animal cells, etc.
- the method of introducing the construct into host cells should be known to those skilled in the art, for example, microinjection, gene gun method, electroporation, virus-mediated transformation, electron bombardment, calcium phosphate precipitation can be used. Law and other methods.
- the fifth aspect of the present invention provides a method for preparing the fusion protein provided by the first aspect of the present invention.
- a suitable method to prepare the fusion protein may include: under suitable conditions
- the expression system provided by the fourth aspect of the present invention is cultivated to express the fusion protein, and the culture containing the fusion protein is collected, and then separated and purified to provide the fusion protein.
- the sixth aspect of the present invention provides a pharmaceutical composition comprising the fusion protein provided in the first aspect of the present invention or the culture of the expression system provided in the fourth aspect of the present invention.
- the content of the fusion protein or culture is usually a therapeutically effective amount.
- therapeutically effective amount generally refers to an amount that can achieve the effect of treating the diseases listed above after a proper administration period. The selection of the preferred therapeutically effective amount can be determined by a person of ordinary skill in the art based on various factors (for example, through clinical trials).
- the factors mentioned include but are not limited to: the pharmacokinetic parameters of the fusion protein of the present invention such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated by the patient, the patient’s weight, the patient’s immune status, Ways and so on.
- the formulation has a pH value from 2.0 to 10.0.
- the pharmaceutical composition may also include a pharmaceutically acceptable carrier.
- the carrier may include various excipients and diluents, and these carriers themselves are not essential active ingredients, and there is no excessive toxicity after administration. Suitable carriers should be well known to those skilled in the art. For example, a full discussion of pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J., 1991).
- the pharmaceutical composition can be administered by injection, especially intravitreal injection. Therefore, the pharmaceutical composition is preferably a powder injection (such as a lyophilized powder injection) and a liquid preparation. .
- the seventh aspect of the present invention provides the use of the fusion protein provided in the first aspect of the present invention and the pharmaceutical composition provided in the sixth aspect of the present invention in the preparation of medicines, and the medicines may be selected from for the treatment of ocular angiogenesis-related diseases medicine.
- Ocular angiogenesis-related diseases usually refer to related diseases that damage the structure and function of the eye due to the appearance of new blood vessels in mature tissues such as the cornea, iris, choroid, retina, and optic disc of the eye.
- ocular angiogenesis-related diseases may be corneal neovascularization-related diseases, iris neovascularization-related diseases, retinal neovascularization-related diseases, choroidal neovascularization-related diseases, etc., more specifically, retinal vein occlusion, neovascular glaucoma , Retinal detachment, retinal trauma, retinal macular degeneration, macular edema, etc.
- the fusion protein provided by the present invention has a shorter half-life in serum, but exhibits a good half-life in the vitreous, so that the fusion protein has better targeting and safety. High, can be used in the treatment of ocular angiogenesis-related diseases.
- the eighth aspect of the present invention provides a treatment method comprising: administering to an individual a therapeutically effective amount of the fusion protein provided in the first aspect of the present invention, the culture of the expression system provided in the fourth aspect of the present invention, or the sixth aspect of the present invention The provided pharmaceutical composition.
- treatment includes preventive, curative or palliative treatments that can lead to the desired pharmaceutical and/or physiological effects.
- the effect preferably refers to medically reducing one or more symptoms of the disease or completely eliminating the disease, or blocking or delaying the occurrence of the disease and/or reducing the risk of disease development or deterioration.
- “individual” usually includes humans, non-human primates, or other mammals (such as dogs, cats, horses, sheep, pigs, cows, etc.), which can be based on the use of the preparation, kit or combination The preparations benefit from treatment.
- the fusion protein provided by the present invention has a shorter half-life in serum, but exhibits a good half-life in the vitreous, so that the fusion protein has better targeting properties, and has been proven to be better than the current drugs in the prior art. It has a better half-life and good pharmacological properties.
- the fusion protein provided by the present invention also has good stability and low viscosity, and thus has a good industrialization prospect.
- MOLECULAR CLONING A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel, etc., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley&Sons, New York, 1987 and periodic updates; the series Methods IN ENZYMOLOGY, Academic Press, San Diego; Wolfe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, Vol.
- PCR splicing technology (including primer design, PCR introduction of mutations and restriction digestion, etc.) is a well-known technology well known to those skilled in the art. Those skilled in the art should know that the PCR splicing process of this embodiment is not the only method.
- the target gene can also be obtained through gene synthesis. After successfully obtaining the target gene, clone the target gene into mammalian cell expression vector pTT5 (Yves Durocher), and transform E. coli Top10F'; after identification of the positive clone, inoculate it in 500ml LB medium, cultivate it overnight, and collect the bacteria by centrifugation. Omega Endo-Free Plasmid Maxi Kit or similar method to extract plasmid.
- the fusion protein prepared in Example 1 was purified through the following steps:
- fusion proteins that do not contain hydrophilic repetitive sequences: Treat a 50ml Protein A column (alkali-resistant Protein A, Borgron, AA0273) with 0.1M NaOH at a flow rate of 2ml/min to remove the remaining protein on the column; 100mM Glycine 20mM Cit pH3.2 equilibrate at least 2 column volumes, and then equilibrate at least 2 column volumes with 150mM NaCl 20mM PB (pH 6.7) until the pH reaches 6.7 and the conductivity is 15mS/cm; at the same time, take 1L of the medium supernatant Centrifuge at 5000 rcf for 20 minutes, separate the precipitate, and take the supernatant; then filter with a 0.22 ⁇ m microporous filter to remove cell debris, test the turbidity of the sample to be below 20NTU, save the sample 1ml; pass the medium filtrate through the Protein at a flow rate of 10ml/min A chromatography column, the residence time on the column
- fusion protein containing hydrophilic repeating sequence After purification by the above-mentioned Protein A, it is further purified by 50ml anion chromatography (Q Bestarose FF, Borglong, AI0024). Equilibrate at least 2 column volumes with 500mM NaCl 20mM Cit pH6.0, and then equilibrate at least 5 column volumes with 20mM CitNa pH6.0 until the pH reaches 6.0 and the conductivity is about 3mS/cm; Purify the protein A sample at 10ml/cm.
- the flow rate of min passes through the Q Bestarose FF chromatography column, and the residence time on the column is about 5 minutes; equilibrate at least 5 column volumes with 20mM CitNa pH6.0 until the 280nm absorbs below 3mAU; wash with 40% 500mM NaCl 20mM Cit pH6.0
- the elution peak is collected according to the absorption value of 280nm; the elution peak is collected with 100% 500mM NaCl 20mM Cit pH6.0, and the elution peak is collected according to the absorption value of 280nm, and stored at 4°C or -20°C.
- VEGF receptor KDR human VEGF receptor KDR
- Ang-2 protein (10691-H08H, Sino Biological Inc) and dilute it to 1ug/ml with 50mM NaHCO 3 pH9.6 buffer.
- PBS containing 0.01% Tween-20 and 1% BSA
- VEGF-A 165 final concentration 80ng/ml
- 50 ⁇ l per well is added to a 96-well plate and placed in a 37°C incubator to antagonize for 1h; 10-cm dish
- HUVEC cells ScienceCell, Cat#8000
- trypsin 1.5ml trypsin
- ECM+1% medium ScienceCell, Cat#1001, containing FBS, 100XPS and ECGS
- SD rats were randomly divided into groups, 5 in each group, and injected subcutaneously with the fusion protein in Table 4 at 2 mg/kg.
- the fusion protein administration group was 3h, 8h, 12h, 24h, 36h, 48h, 72h before and after injection.
- Blood was collected at 96h, 120h, 144h, 168h, and serum was separated.
- the sandwich ELISA method was used to detect the pharmacokinetics of the fusion protein in rats. 100ng/well of hArg1VEGF was coated overnight, and washed with PBST 3 times. After the 5% skimmed milk powder was blocked, washed with PBST 3 times, the serum at each time point was diluted to the specified multiple, and 100 ⁇ l/well was added to the ELISA plate.
- DAY 0 Binocular fundus laser induced CNV model, the number of laser burning in each eye is 6-8, laser parameters: wavelength 532nm; power 500mW; spot diameter 50um; exposure time 100ms.
- DAY 15 After being judged as a mold by FFA, the cynomolgus monkeys were evenly grouped according to gender and the leakage area of the fourth-level spot, each group of 6 animals, and drug intervention according to the group and dose in the following table, injection method: intravitreal injection, 50 ⁇ l/eye.
- the average thickness improvement rate of the subretinal hyperreflective signal substance (SHRM) of each group is shown in Figure 3.
- SHRM thickness the average thickness of SHRM before administration-the average thickness of SHRM after administration
- improvement rate of average SHRM thickness (%) reduction in average SHRM thickness/average SHRM thickness before administration x 100%. It can be seen from Figure 3 that compared to the control group, each group obtained a better SHRM average thickness improvement rate, and basically reached or better than the level of the positive control group.
- the monkey CNV model has good efficacy.
- Figure 4 exemplarily shows the improvement of DR301AbB4's spot rate and leakage area. It can be seen from Figure 4 that DR301AbB4 can significantly reduce the number of level 4 spots and improve the leakage area (it gradually shrinks as time goes by).
- the present invention effectively overcomes various shortcomings in the prior art and has a high industrial value.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
样品名称 | PdI | 体积分布,单体峰粒径(d.nm) |
Bevacizumab | 0.42±0.13 | 9.82±0.16 |
DR301DpB01 | 0.494±0.14 | 9.383±0.33 |
DR301DpB2 | 0.788±0.18 | 19.13±0.63 |
DR301DpM2 | 0.493±0.15 | 19.28±0.11 |
DR301DpM5 | 0.424±0.04 | 17.46±1.15 |
DR301LtB1 | 0.418±0.07 | 18.71±0.49 |
DR301AbB4 | 0.611±0.10 | 19.51±0.21 |
DR301AbB8 | 0.524±0.08 | 19.09±0.80 |
Claims (17)
- 一种融合蛋白,所述融合蛋白包括亲水性重复序列片段、拮抗VEGF片段、免疫球蛋白Fc片段。
- 如权利要求1所述的融合蛋白,其特征在于,所述亲水性重复序列片段选自类明胶蛋白片段、或多肽复合单元片段。
- 如权利要求2所述的融合蛋白,其特征在于,所述亲水性重复序列片段包括:a)氨基酸序列如SEQ ID No.28~29其中之一所示的多肽片段;或,b)氨基酸序列与SEQ ID No.28~29其中之一具有90%以上序列一致性且具有a)限定的多肽片段的功能的多肽片段;或,c)氨基酸序列如SEQ ID No.30所示的多肽片段;或,d)氨基酸序列与SEQ ID No.30具有90%以上序列一致性且具有c)限定的多肽片段的功能的多肽片段。
- 如权利要求1所述的融合蛋白,其特征在于,所述拮抗VEGF片段包括:e)氨基酸序列如SEQ ID No.1~7其中之一所示的多肽片段;或,f)氨基酸序列与SEQ ID No.1~7其中之一具有90%以上序列一致性且具有e)限定的多肽片段的功能的多肽片段。
- 如权利要求1所述的融合蛋白,其特征在于,所述免疫球蛋白Fc片段包括:g)氨基酸序列如SEQ ID No.33~41其中之一所示的多肽片段;或,h)氨基酸序列与SEQ ID No.33~41其中之一具有90%以上序列一致性且具有g)限定的多肽片段的功能的多肽片段;所述免疫球蛋白Fc片段为人源的。
- 如权利要求1所述的融合蛋白,其特征在于,所述融合蛋白还包括连接肽片段,优选的,所述连接肽片段富含G、S和/或A。
- 如权利要求6所述的融合蛋白,其特征在于,所述连接肽片段包括氨基酸序列如SEQ ID NO.42-43其中之一所示的多肽片段。
- 如权利要求1所述的融合蛋白,其特征在于,所述融合蛋白还包括拮抗Ang片段,所述拮抗Ang片段选自拮抗Ang-1片段、或拮抗Ang-2片段。
- 如权利要求1或8任一权利要求所述的融合蛋白,其特征在于,所述亲水性重复序列片段位于融合蛋白的N端和/或C端,所述拮抗VEGF片段位于免疫球蛋白Fc片段的N端或C端;和/或,拮抗VEGF片段、或拮抗Ang片段独立地位于免疫球蛋白Fc片段的N端或C 端,优选的,拮抗VEGF片段、拮抗Ang片段分别位于免疫球蛋白Fc片段的N端和C端。
- 如权利要求1所述的融合蛋白,其特征在于,所述融合蛋白的氨基酸序列包括SEQ ID NO.11-12、SEQ ID NO.15-16、SEQ ID NO.18-19其中之一所示的序列;或,所述融合蛋白的氨基酸序列包括SEQ ID NO.20和SEQ ID NO.21所示的序列、SEQ ID NO.22和SEQ ID NO.24所示的序列、SEQ ID NO.23和SEQ ID NO.24所示的序列、SEQ ID NO.25和SEQ ID NO.7所示的序列、或SEQ ID NO.26和SEQ ID NO.27所示的序列。
- 一种分离的多核苷酸,编码如权利要求1~10任一权利要求所述的融合蛋白。
- 一种构建体,所述构建体含有如权利要求11所述的分离的多核苷酸。
- 一种表达系统,所述表达系统含有如权利要求12所述的构建体或基因组中整合有外源的如权利要求11所述的多核苷酸。
- 如权利要求1-10任一权利要求所述的融合蛋白的制备方法,包括:在合适的条件下培养如权利要求13所述的表达系统,使之表达所述融合蛋白,分离、纯化以提供所述融合蛋白。
- 一种药物组合物,包括如权利要求1-10之任一权利要求所述的融合蛋白或如权利要求13所述的表达系统的培养物。
- 如权利要求1-10任一权利要求所述的融合蛋白、如权利要求15所述的药物组合物在制备药物中的用途。
- 如权利要求16所述的用途,其特征在于,所述药物选自用于眼部血管新生相关疾病的药物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010197997.X | 2020-03-19 | ||
CN202010197997.XA CN113493519B (zh) | 2020-03-19 | 2020-03-19 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021185051A1 true WO2021185051A1 (zh) | 2021-09-23 |
Family
ID=77769486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/078081 WO2021185051A1 (zh) | 2020-03-19 | 2021-02-26 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113493519B (zh) |
WO (1) | WO2021185051A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114014940B (zh) * | 2021-11-25 | 2022-11-15 | 华兰基因工程有限公司 | 一种2019-nCoV表面蛋白受体结合区融合蛋白制备方法 |
CN117304307A (zh) * | 2022-06-27 | 2023-12-29 | 上海鼎新基因科技有限公司 | 一种治疗新生血管相关眼底疾病的aav药物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103641896A (zh) * | 2009-11-19 | 2014-03-19 | 浙江大学 | 明胶样单元的用途 |
CN107001457A (zh) * | 2014-11-25 | 2017-08-01 | 瑞泽恩制药公司 | 用于治疗血管性眼病的方法和制剂 |
CN109310756A (zh) * | 2016-05-13 | 2019-02-05 | 奥美药业有限公司 | 新型血管生成素2,vegf双特异性拮抗剂 |
CN110612124A (zh) * | 2017-03-22 | 2019-12-24 | 豪夫迈·罗氏有限公司 | 用于治疗眼部病症的优化的抗体组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7625564B2 (en) * | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
WO2016005381A1 (en) * | 2014-07-10 | 2016-01-14 | Bayer Pharma Aktiengesellschaft | Pdgfrbeta-fc fusion proteins and uses thereof |
US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
-
2020
- 2020-03-19 CN CN202010197997.XA patent/CN113493519B/zh active Active
-
2021
- 2021-02-26 WO PCT/CN2021/078081 patent/WO2021185051A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103641896A (zh) * | 2009-11-19 | 2014-03-19 | 浙江大学 | 明胶样单元的用途 |
CN107001457A (zh) * | 2014-11-25 | 2017-08-01 | 瑞泽恩制药公司 | 用于治疗血管性眼病的方法和制剂 |
CN109310756A (zh) * | 2016-05-13 | 2019-02-05 | 奥美药业有限公司 | 新型血管生成素2,vegf双特异性拮抗剂 |
CN110612124A (zh) * | 2017-03-22 | 2019-12-24 | 豪夫迈·罗氏有限公司 | 用于治疗眼部病症的优化的抗体组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN113493519B (zh) | 2022-12-27 |
CN113493519A (zh) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210069293A1 (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
KR101698362B1 (ko) | Vegf-a 수용체 상호작용을 억제하는 결합 단백질 | |
US11518798B2 (en) | Vascular endothelial growth factor receptor targeting peptide-elastin fusion polypeptides | |
EP2867360B1 (en) | Designed ankyrin repeat proteins binding to platelet-derived growth factor | |
WO2021185051A1 (zh) | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 | |
AU2016241499B2 (en) | Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused | |
RO119721B1 (ro) | Antagonişti ai factorului de creştere al celulelor vasculare endoteliale | |
JP2003159083A (ja) | 新規な神経栄養因子 | |
CN117467025B (zh) | 一种抗vegf和补体双功能融合蛋白及其应用 | |
WO2023109835A1 (zh) | 一种vegf-crm197重组融合蛋白疫苗及其制备方法和应用 | |
KR101466875B1 (ko) | 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료 | |
US11548931B2 (en) | PASylated VEGFR/PDGFR fusion proteins and their use in therapy | |
KR101482237B1 (ko) | 항 il-6r 및 tnfr2을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 자가 면역 질환 치료용 약학 조성물 | |
RU2669787C2 (ru) | Средство для лечения заболевания, сопровождающегося отеком макулы вследствие повышенной экспрессии VEGF-A | |
US20130225505A1 (en) | Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye | |
CN117858907A (zh) | 一种TGF-β/VEGF双功能抗体融合蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21772627 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21772627 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21772627 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03.07.2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21772627 Country of ref document: EP Kind code of ref document: A1 |